Last reviewed · How we verify

NCT05432024: ENABLE-CMR

Evaluation of Ablation Lesions Using Cardiovascular Magnetic Resonance Imaging

Recruiting now Last updated 28 July 2025
What this trial tests

trial testing Catheter ablation in Atrial Fibrillation in 60 participants. Currently enrolling.

Timeline
8 March 2023
Primary endpoint
1 April 2028
1 April 2028

Quick facts

Lead sponsorR&D Cardiologie
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment60
Start date8 March 2023
Primary completion1 April 2028
Estimated completion1 April 2028
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

R&D Cardiologie — full company profile →

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ineffective ablation lesions can cause arrhythmia recurrence after catheter ablation for cardiac arrhythmia. Ablation lesions can be created with various ablation energy modalities. This study uses cardiovascular magnetic resonance imaging to evaluate the ablation lesion characteristics of radiofrequency ablation, ultra-low temperature cryo ablation, and pulsed field ablation. The ablation lesion characteristics of different energy characteristics will be compared. Additionally, arrhythmia recurrence and quality of life will be evaluated for the different energy modalities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Catheter ablation

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other R&D Cardiologie trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05432024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing